Shattuck Labs

STTK

Market cap $601M

AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced the pricing of its previously announced a public offering of 10,879,376 shares of its common stock at a public offering price per share of $4.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 7,870,624 shares of its common stock at a public offering price of $3.9999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.0001 per share and are exercisable immediately. The aggregate gross proceeds to Shattuck from the offering are expected to be approximately $75 million before deducting underwriting discounts and commissions and other offering expenses payable by Shattuck, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on June 11, 2026, subject to the satisfaction of customary closing conditions. In addition, Shattuck has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,812,500 shares of its common stock at the public offering price, less underwriting discounts and commissions.

AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it has commenced a public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Shattuck expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Shattuck.

AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced it has received notices to exercise totaling approximately 50.6 million common stock warrants to date, representing approximately 96% of the warrants issued in the Company's August 4, 2025 private placement.

Shattuck Labs, Inc. (STTK) Discusses Phase I Results for DR3 Blocking Antibody SL-325 and Pipeline Update Transcript

Shattuck Labs Inc. (NASDAQ:STTK) stock is down on Monday following news regarding its lead drug candidate, SL-325.

AUSTIN, TX and DURHAM, NC, June 08, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced data from its Phase 1 clinical trial of SL-325, Shattuck's lead DR3 blocking antibody candidate.

AUSTIN, Texas and DURHAM, N.C., June 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it will host an investor call and webcast on Monday, June 8, 2026 at 8:00 a.m. ET to present comprehensive Phase 1 clinical data for SL-325, including safety, tolerability, pharmacokinetics, receptor occupancy, pharmacodynamic and immunogenicity results and provide a pipeline update.

AUSTIN, Texas and DURHAM, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2026 and provided recent business highlights.

The biotech published its final earnings report and business covering 2025. It posted a slightly narrower-than-expected net loss for the fourth quarter.

AUSTIN, Texas and DURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided recent business highlights.